STYLE SHEET
GLOBAL CSS
COLORS
ANIMATIONS
MEDIA QUERY
SPACING SYSTEM

Why only for healthcare professionals?

The content on these information pages is directed solely at you if you are a doctor, nurse, or pharmacist, as it concerns treatment with prescription medicines.

Please confirm that you are a healthcare professional (healthcare assistant, nurse, doctor, psychologist, or other licensed healthcare professional).

Back to main page

Confirm and continue

Discover Annie's sustainable weight loss journey with Yazen

Weight loss breakthrough: how one woman lost 1.5 stone with Wegovy

AnnieDalby's weight loss journey is a testament to the potential of modern medical interventions. After years of struggling with her weight and trying numerous diets, including WeightWatchers, Slimming World, and the "fairly extreme" Cambridge Diet, Annie has found success with the weight-loss medication Wegovy alongside Yazen.

A transformative personal experience

Since mid-May, Annie has lost an impressive 21 pounds using semaglutide, the active ingredient in Wegovy. However, her transformation goes far beyond mere numbers.She describes the medication as life-changing, comparing it to "having a brain transplant" and completely eliminating what she calls "food noise" – the constant, overwhelming thoughts about eating that had dominated her life for years.

Understanding the medication

Wegovy works by targeting the brain's reward system, helping patients feel fuller and reducing the constant preoccupation with food. Dr Elin Skoglund from Yazen explains that the medication can provide a sense of relief by diminishing the distractions of constant food thoughts.

The medication is not a magic solution but a tool for those with specific health needs. The NHS prescribes Wegovy only for individuals with weight-related health problems and a certain body mass index (BMI). It must be used inc ombination with diet and exercise and is particularly helpful for those who have struggled to lose weight through traditional methods.

Annie's personal history adds depth to her success – she has an underactive thyroid, a condition triggered during her second pregnancy, which had previously made weight loss challenging. Despite these obstacles, Wegovy has provided her with a breakthrough.

Potential side effects and professional guidance

While Annie's experience is overwhelmingly positive, medical professionals like DrDeborah Lee caution that the medication can have side effects. These may include nausea, diarrhoea, vomiting, constipation, stomach pain, and bloating.As with any medical treatment, it's crucial to consult healthcare professionals and undergo careful monitoring.

A broader perspective on weight management

The BritishHeart Foundation has noted additional benefits of Wegovy, including its potential to lower the risk of heart attacks and strokes in patients with heart and circulatory diseases. This highlights that weight management medications can offer benefits beyond weight loss.

Annie's story is more than just a weight loss success – it's a narrative of reclaiming control, reducing mental stress around eating, and improving overall quality of life.

If you’d like to hear more about Annie’s Yazen journey, check out her patient testimonial here.

Read the full article here.

Start your weight loss journey with Yazen today

Everything you need to do is to create an account and answer some questions about your health

Get Started
Get Started
Get Started

More news

Press release
Yazen expands in Scandinavia through the acquisition of Medstart

Yazen expands in Scandinavia through the acquisition of Danish company Medstart, which is established in Denmark and Norway. Together, they enhance care for people with obesity.

Press release
Yazen Health closes €19.5M series A to drive global growth

Yazen Health has successfully closed an oversubscribed €19.5 million series A funding round to fuel its international expansion. This investment enables Yazen to enhance its pioneering obesity treatment model, combining modern weight loss medication with comprehensive lifestyle support.

News
Sifted UK: Yazen raises €19.5m to expand obesity treatment in the EU

Yazen has secured €19.5 million in Series A funding to expand its GLP-1-based obesity treatment across Europe. The company combines medication with lifestyle support for sustainable weight loss results.